中国が世界初の侵襲型BCIを承認 ― なぜNeuralinkではないのか?
中国の国家薬品監督管理局が、脊髄損傷患者向けのneuracleのneo脳インプラントを承認。侵襲型BCIとして初の承認となり、neuralinkに先んじて市場に登場することになった。
china approved the neo device, developed by neuracle technology and tsinghua university, for patients with quadriplegia due to spinal cord injuries, marking the first regulatory green light for an invasive bci globally. the system uses sensors placed on the brain's outer membrane to interpret signals and drive external robotics, offering a safer profile than neuralink's penetrating threads by reducing hemorrhage risk. this milestone highlights china's accelerated regulatory pathway for neurotech, granting it a first-mover advantage in the commercial bci market ahead of us competitors.